Literature DB >> 1980610

Loss of genetic information in central nervous system tumors common to children and young adults.

C D James1, J He, E Carlbom, T Mikkelsen, P A Ridderheim, W K Cavenee, V P Collins.   

Abstract

The clonal loss of genetic information as revealed by the comparison of normal and tumor DNA restriction fragment length alleles has permitted the determination of the genomic positions of cancer-recessive mutations. Here we have applied this approach to the analysis of 19 central nervous system tumors that constitute four histologic groups and occur most frequently in children and young adults. The detectable loss of genetic information from cases of medulloblastoma (11 examined) indicates that among such tumors, loss occurs most frequently from the short arm of chromosome 17. For the ependymomas examined (four cases), chromosome 22 was the preferred site for detectable loss. Analysis of pilocytic astrocytomas of the cerebellum (three cases) failed to reveal genetic alterations of any type among such tumors, a finding unique to this histologic group. The single choroid plexus papilloma examined demonstrated loss of genetic information from chromosome 3. Among the 19 tumors, multiple cases of loss were observed from chromosomes 10, 11, 13, and 22, and from the short arm of chromosome 17. Therefore, with regard to the chromosomal locations of implied tumor suppressor genes, these results are consistent with those described for intracranial tumors occurring more commonly in adults of middle to advanced age.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980610     DOI: 10.1002/gcc.2870020204

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Infrequency of p53 gene mutations in ependymomas.

Authors:  K L Fink; E J Rushing; S C Schold; P D Nisen
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Molecular genetic studies of chromosome 11 and chromosome 22q DNA sequences in pediatric medulloblastomas.

Authors:  S Lescop; A Lellouch-Tubiana; G Vassal; C Besnard-Guerin
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

4.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 5.  LGI1: a gene involved in epileptogenesis and glioma progression?

Authors:  W Gu; E Brodtkorb; T Piepoli; G Finocchiaro; O K Steinlein
Journal:  Neurogenetics       Date:  2005-04-13       Impact factor: 2.660

Review 6.  Tumor suppressor genes and medulloblastoma.

Authors:  P H Cogen; J D McDonald
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

7.  Deletions on the long arm of chromosome 17 in pilocytic astrocytoma.

Authors:  A von Deimling; D N Louis; A G Menon; K von Ammon; I Petersen; D Ellison; O D Wiestler; B R Seizinger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.

Authors:  E Karamitopoulou; E Perentes; I Diamantis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours.

Authors:  C M Phelan; L Liu; M H Ruttledge; K Müntzning; P A Ridderheim; V P Collins
Journal:  Hum Genet       Date:  1995-12       Impact factor: 4.132

10.  Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood.

Authors:  D Schiffer; P Cavalla; A Di Sapio; M T Giordana; A Mauro
Journal:  Childs Nerv Syst       Date:  1995-09       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.